Business strategy in drug development articles within Nature Reviews Clinical Oncology

Featured

  • News & Views |

    The affordability of newly approved anticancer agents is a challenge to many national health services and reimbursement systems. Therefore, we have developed an approach based upon the adoption of a novel model of price setting and herein provide examples of how it might be implemented. This model is intended to alter the balance between social and economic entrepreneurship.

    • Carin A. Uyl-de Groot
    •  & Bob Löwenberg

  • Opinion |

    The costs of both newly approved, and established anticancer drugs have risen dramatically in the past decade, to the point where the costs of such treatments are becoming unsustainable. In this perspective, the authors outline the extent of this problem, and how it is likely to continue, while also suggesting measures that could be taken in future to address these rising costs.

    • Vinay Prasad
    • , Kevin De Jesús
    •  & Sham Mailankody

  • News & Views |

    Imatinib has revolutionized the treatment of chronic myeloid leukaemia (CML). In 2016, generic imatinib will be introduced into the US market. We analyse the potential impact of this new product on patient care and optimal CML therapy, and comment on the effect that distorted cancer drug pricing in the USA will have on treatment for patients with limited therapeutic options.

    • Larry Gorkin
    •  & Hagop Kantarjian

  • News & Views |

    A study reveals that, from 2009–2014, a considerable percentage of public speakers at Oncologic Drugs Advisory Committee meetings had disclosed or undisclosed financial associations with the drug company seeking product approval. Amid calls for increased public engagement in health care and health-care research, steps must be taken to minimize the conflicts of interests of those who claim to speak for patients and the public.

    • Matthew S. McCoy
    •  & Ezekiel J. Emanuel

  • News & Views |

    Accurate and efficient expedited investigational new drug (IND) reporting is a crucial component of clinical research. The FDA, pharmaceutical companies, institutional review boards, and clinical investigators should develop dynamic standardized electronic forms with preferred, predetermined terms to harmonize their practices and to help optimize the quality of clinical research and maximize patient safety.

    • Apostolia M. Tsimberidou

  • News & Views |

    A survey on the official prices of 31 cancer drugs across 18 countries, published by Vogler and colleagues, has revealed substantial differences in price for the same drug in different countries. Herein, we discuss inequalities in the access to cancer care and raise some challenging questions.

    • Richard Sullivan
    •  & Ajay Aggarwal

  • News & Views |

    A qualitative study indicates that there is a positive selection bias towards favourable economic analysis of targeted therapies, when these are funded by the manufacturer. At a time of increasing budgetary constraints and public scrutiny of the relationship between industry and the professions, we need a more mixed economy of funding for this field.

    • David Kerr
    •  & Ahmed Elzawawy

  • Opinion |

    The use of therapy that is truly targeted to the needs and biological requirements of an individual patient is an aim for many in the oncology field. Jackson and Sood discuss the implications of targeted therapies on patients and the health-care system and discuss methods that might be used to maximize efficiency, cost effectiveness and patient survival.

    • David B. Jackson
    •  & Anil K. Sood

Browse broader subjects

Browse narrower subjects

Browse Business strategy in drug development across other nature.com journals